Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $94.5 million.

  • Tango Therapeutics' Short-term Investments fell 6065.76% to $94.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.5 million, marking a year-over-year decrease of 6065.76%. This contributed to the annual value of $188.4 million for FY2024, which is 3035.6% down from last year.
  • As of Q3 2025, Tango Therapeutics' Short-term Investments stood at $94.5 million, which was down 6065.76% from $141.5 million recorded in Q2 2025.
  • Tango Therapeutics' Short-term Investments' 5-year high stood at $350.0 million during Q1 2022, with a 5-year trough of $94.5 million in Q3 2025.
  • Moreover, its 5-year median value for Short-term Investments was $276.4 million (2023), whereas its average is $257.1 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 11150.56% in 2021, then crashed by 6065.76% in 2025.
  • Tango Therapeutics' Short-term Investments (Quarter) stood at $342.5 million in 2021, then fell by 10.61% to $306.2 million in 2022, then dropped by 11.65% to $270.5 million in 2023, then crashed by 30.36% to $188.4 million in 2024, then tumbled by 49.85% to $94.5 million in 2025.
  • Its Short-term Investments was $94.5 million in Q3 2025, compared to $141.5 million in Q2 2025 and $158.3 million in Q1 2025.